IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4291
Positioning
Market Dominance
Manufacturing
Medical Equipment
$39M
James E. Besser
Modular Medical, Inc., a development stage medical device company, focuses on the design, development, and commercialization of insulin pumps. The company is headquartered in San Diego, California.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$MODD Modular Medical, Inc. | 33 | 19 | 16 | 17 | - | - | -453.3% | -259.8% | - | - | - | - | 0.0% | 74.0x | $39M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
Modular Medical, Inc. (MODD) receives a "Avoid" rating with a composite score of 33.1/100. It ranks #4291 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
James E. Besser
Chief Executive Officer
Labor Force
20
19
25
43
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for MODD
Lagging peers — losers tend to keep underperforming
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
Average volatility — neutral timing signal
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for MODD.
View All RatingsInsufficient data for Financial Analysis
ROE proxy -453.3% (sector -2.5%)
GM N/A vs sector 43%, OM N/A vs sector 1%
Capital turnover N/A
Rev growth N/A, 11yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our quantitative model flags Modular Medical, Inc. with an Avoid rating, assigning a composite score of 33.1/100 and 1 out of 5 stars. Ranked #4291 of 7,333 stocks, MODD falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
Modular Medical, Inc. registers a weak quality score of just 19/100, indicating significant profitability challenges. The company reports a return on equity of -453.3% (sector avg: -2.5%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.
MODD registers a value score of just 16/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 6.47x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
Modular Medical, Inc.'s investment score of 25/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of -259.8% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
Modular Medical, Inc. is experiencing notably weak momentum with a score of just 17/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth data is not currently available, while a beta of 0.86 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
MODD's stability score of 43/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 0.86 and a debt-to-equity ratio of 74.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
MODD's short interest factor score of 80/100 indicates very low short selling activity relative to peers — a positive signal suggesting institutional investors see limited near-term downside. Specific risk factors include elevated leverage (D/E: 74.00x), micro-cap liquidity risk. As a micro-cap company with a market capitalization of $39M, Modular Medical, Inc. benefits from the generally lower volatility and deeper liquidity associated with its size class.
Modular Medical, Inc. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4291 of 7,333 overall (41st percentile). Key comparisons include ROE of -453.3% trailing the -2.5% sector median. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While MODD currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Value (16) would have the largest impact on the composite score.
ROE 18177% ABOVE SECTOR MEDIAN (FAVORABLE)
Debt/Equity 36900% ABOVE SECTOR MEDIAN
Div. Yield NaN% BELOW SECTOR MEDIAN
AUDIT DATA AS OF DEC 31, 2025 (Q3 FY2025)
We rate Modular Medical, Inc. (MODD) as Avoid with a composite score of 33.1/100 at a current price of $0.47. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.
The rating is primarily driven by strength in stability (43th percentile) and investment (25th percentile), which together account for the majority of the composite score. Offsetting weakness in value (16th percentile) and momentum (17th percentile) tempers our overall conviction. We assign a No Moat rating (19/100), High uncertainty, and Poor capital allocation.
Key items to watch: momentum to confirm whether the current price trend has legs; valuation compression risk if growth disappoints. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
Modular Medical, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 33.1/100 places it at rank #4291 in our full 7,333-stock universe. At $39M in market capitalization, Modular Medical, Inc. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Momentum indicators (17th percentile) suggest caution regarding the near-term price trend. Revenue growth data is unavailable, limiting our ability to confirm whether momentum is fundamentally supported.
Margin data is not available for Modular Medical, Inc., which limits our assessment of the company's cost structure and operating efficiency. We rely on factor-based signals to infer business quality in the absence of detailed margin data.
At a current price of $0.47, Modular Medical, Inc. is trading at a premium to fundamental value. Our value factor score of 16/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at P/B of 6.5x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
The stock may offer contrarian value if near-term headwinds prove transitory — the current weakness in factor scores may reverse if business fundamentals stabilize.
The Avoid rating (composite 33.1/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Weak momentum (17th percentile) suggests institutional selling pressure and unfavorable technical dynamics that may persist.
Below-average quality (19th percentile) raises durability concerns about the fundamental profile and increases the risk of negative earnings surprises.
Elevated short interest (80th percentile) indicates that sophisticated market participants are betting against the stock.
We assign a High uncertainty rating to Modular Medical, Inc.. Key risk factors include weak quality scores (19th percentile). The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.
Specific risk factors that inform our assessment include: weak quality scores (19th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 43th percentile and quality factor at the 19th percentile provide a quantitative summary of the overall risk landscape.
We identify limited risk mitigants at this time, which contributes to our high uncertainty assessment. Investors should monitor for improvement in balance sheet metrics, margin stability, and business predictability that could warrant a downgrade in our risk assessment over time.
We rate Modular Medical, Inc.'s capital allocation as Poor. Key concerns include low returns on equity (-453.3%), weak asset returns (ROA -259.8%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — Modular Medical, Inc. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, Modular Medical, Inc. receives a Avoid rating with a composite score of 33.1/100 (rank #4291 of 7,333). Our quantitative framework assigns a No Moat (19/100, trend: stable), High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 24/100.
Our analysis does not support a constructive view on Modular Medical, Inc. at this time. The combination of limited competitive advantages, high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign Modular Medical, Inc. a meaningful economic moat, scoring 19/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, margin superiority, reached only 10/20.
The strongest moat sources are margin superiority (10/20) and financial resilience (5.8/20). GM N/A vs sector 43%, OM N/A vs sector 1%. Interest coverage N/A. These pillars form the core of Modular Medical, Inc.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include reinvestment efficiency (0/20) and growth durability (0.6/20). Capital turnover N/A. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect Modular Medical, Inc.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers are not clearly identifiable from current fundamentals. This may reflect a company in transition, a cyclical downturn, or structural challenges in the business model. We assign a quality factor of 19/100 which further underscores our concern regarding earnings sustainability.
Return metrics include ROE of -453.3% and ROA of -259.8%. Relative to the Manufacturing sector, sector comparison data is limited, and ROE of -453.3% compares to a sector median of -2.5%.
The balance sheet reflects moderate leverage with D/E of 74%. The sector median D/E is 0%, putting Modular Medical, Inc. at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
Above 50MA
37.18%
Net New Highs
+51081
Viewing insider transactions for Modular Medical, Inc.'s ( NASDAQ:MODD ) over the last year, we see that insiders were...
SAN DIEGO, CA / ACCESS Newswire / December 10, 2025 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult ...
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 80% to $6.14 after the company announced it received notice of acceptance from the Australian patent office for its patent application for Combination of Opioids and N-Acylethanolamines for pain treatment. Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) gained 53.1% to $0.3264 after the company received an Innovation Technology contract from Vizient for its novel AI-driven precision heart disease tests. Verve Therapeutics, Inc. (NASDAQ: VERV) jumped 27% to $11.95. Eli Lilly said it will acquire rights under Beam Therapeutics’ amended collaboration and license agreement with Verve, including rights to co-develop and co-commercialize Verve's base editing programs for cardiovascular disease. BioVie Inc. (NASDAQ: BIVI) rose 23.6% to $4.7840. Wolfspeed, Inc. (NYSE: WOLF) jumped 22.7% to $34.02 after the company reported first-quarter earnings. Repligen Corporation (NASDAQ: RGEN) gained 20.5% to $137.65 following better-than-expected results. Mullen Automotive, Inc. (NASDAQ: MULN) rose 20.1% to $0.3051. YanGuFang International Group Co., Ltd. (NASDAQ: YGF) gained 19.5% to $2.81. Shutterstock, Inc. (NYSE: SSTK) climbed 18.6% to $40.71 after the company posted upbeat third-quarter results and raised FY23 outlook. Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) rose 17.7% to $23.21 following third-quarter results. Avalo Therapeutics, Inc. (NASDAQ: AVTX) shares gained 17.5% to $0.1090 after the company announced it has completed the divestiture of AVTX-800 Series. Pinterest, Inc. (NYSE: PINS) shares rose 16.9% to $29.34 after the company reported better-than-expected third-quarter financial results and issued guidance. Two Harbors Investment Corp. (NYSE: TWO) climbed 16.8% to $11.74 following quarterly results. Conduit Pharmaceuticals Inc. (NASDAQ: CDT) rose 16.5% to $1.83. Femasys Inc. (NASDAQ: FEMY) gained 16.5% to $1.62. Modular Medical, Inc. (NASDAQ: MODD) jumped 15% to $1.23. Evaxion Biotech A/S (NASDAQ: EVAX) climbed 14.8% to $1.09. Insperity, Inc. (NYSE: NSP) gained 14.3% to $110.31 following upbeat results. EUDA Health Holdings Limited (NASDAQ: ...
Gainers MingZhu Logistics Holdings Limited (NASDAQ: YGMZ) shares gained 64% to $0.7798 after gaining more than 10% on Friday. PCTEL, Inc. (NASDAQ: PCTI) climbed 47.3% to $6.86. On Friday, Amphenol Corp (NYSE: APH) inked a deal to acquire PCTEL for around $139.7 million. Almacenes Éxito S.A. (NYSE: EXTO) shares rose 32.6% to $6.66. MMTec, Inc. (NASDAQ: MTC) surged 30% to $0.7608. Tempest Therapeutics, Inc. (NASDAQ: TPST) gained 29% to $4.72. LQR House Inc. (NASDAQ: LQR) shares climbed 24.5% to $0.2148. LQR House announced that through its custom marketing campaign and strategic efforts, Von Payne Whiskey is now displayed on the shelves of the retail giant, Costco. Secoo Holding Limited (NASDAQ: SECO) rose 23% to $0.7868 after declining 37% on Friday. Ensysce Biosciences, Inc. (NASDAQ: ENSC) climbed 22.2% to $1.76. E2open Parent Holdings, Inc. (NYSE: ETWO) gained 22% to $3.00. Elliott Investment Management L.P. reported a 9% stake in E2open Parent Holdings as of Oct. 13. Inotiv, Inc. (NASDAQ: NOTV) climbed 21.2% to $2.4850. Zapp Electric Vehicles Group Limited (NASDAQ: ZAPP) gained 21.2% to $0.6195. Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) shares jumped 20.8% to $0.5799 after jumping 45% on Friday. Mereo BioPharma Group plc (NASDAQ: MREO) climbed 20% to $1.55. Ultragenyx and Mereo BioPharma announced interim Phase 2 data from Phase 2/3 Orbit study demonstrating setrusumab significantly reduced fracture rates in patients with osteogenesis imperfecta. Prothena Corporation plc (NASDAQ: PRTA) gained 19.7% to $52.78. Alignment Healthcare, Inc. (NASDAQ: ALHC) gained 17.8% to $7.80 after Raymond James upgraded the stock from Outperform to Strong Buy and raised its price target from $9 to $10. Consolidated Communications Holdings, Inc. (NASDAQ: CNSL) surged 17.5% to $4.1493 after the company announced an agreement to be acquired by Searchlight Capital Partners and British Columbia Investment Management. Modular Medical, Inc. (NASDAQ: MODD) gained 17.4% to $1.08. Catalyst Biosciences, Inc. (NASDAQ: CBIO) rose 15.5% to $0.39. indie Semiconductor, Inc. (NASDAQ: INDI) climbed 15% to $5.60. indie Semiconductor expects third-quarter revenue ...
Gainers BioNexus Gene Lab Corp. (NASDAQ: BGLC) shares gained 48.5% to $2.05 in pre-market trading after jumping 30% on Tuesday. Heliogen, Inc. (NYSE: HLGN) shares surged 35.8% to $0.2866 in pre-market trading. Heliogen was granted U.S. patent #11732928 for "Receiver for Capturing Solar Energy." Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) rose 29.3% to $39.77 in pre-market trading after the company said events of retinal vasculitis in treatment with SYFOVRE were rare, with an estimated real-world rate of 0.01% per injection. iTeos Therapeutics, Inc. (NASDAQ: ITOS) rose 23.6% to $14.52 in pre-market trading. ITeos Therapeutics recently reported a loss for the second quarter. Arcus Biosciences, Inc. (NYSE: RCUS) shares rose 22.1% to $22.97 in pre-market trading. Arcus Biosciences recently posted downbeat quarterly results. AIM ImmunoTech Inc. (NYSE: AIM) shares climbed 16.2% to $0.7782 in pre-market trading after gaining 9% on Tuesday. The company recently posted a narrower-than-expected quarterly loss. WISeKey International Holding AG (NASDAQ: WKEY) shares rose 15.7% to $3.24 in pre-market trading. WISeKey International's subsidiary WISe.ART launched ...